Member Info for Chrisatrdg

Good to see 10.53% up today on SP hopefully the start of a turning point for PYC supported by good results & a positive future.I currently have 44,600 shares at a cost of £3.3k & currently showing a loss of £1.6k (48.72% down).I am hoping that this will reverse in the next 6 months.

ValiRx enters final stages of phase I/II trial of its VAL201 prostate cancer drug;
https://www.proactiveinvestors.co.uk/companies/news/207251/valirx-enters-final-stages-of-phase-iii-trial-of-its-val201-prostate-cancer-drug-207251.html

Antrim company seeks £40m EU grant to store UK natural gas
https://www.irishtimes.com/business/energy-and-resources/antrim-company-seeks-40m-eu-grant-to-store-uk-natural-gas-1.3664335?utm_source=dlvr.it&utm_medium=twitter

Results from ValiRx’s phase II study of VAL401 anti-cancer compound to be published on ClinicalTrials.gov

https://www.proactiveinvestors.co.uk/companies/news/207078/results-from-valirxs-phase-ii-study-of-val401-anti-cancer-compound-to-be-published-on-clinicaltrialsgov-207078.html

Hi All - I am glad I topped up this morning & the other day now hopefully for the SP to fly.

RNS Number : 9698D
Infrastrata PLC
15 October 2018




15 October 2018

InfraStrata plc

("InfraStrata" or the "Company")

Islandmagee Gas Storage Project - New EU Grant Application

InfraStrata plc (AIM: INFA), the UK quoted company focused on the development of natural gas storage capacity, is pleased to announce that it has submitted a new "grant for works" application in respect of its Islandmagee gas storage project (the "Project") to the EU (European Union) pursuant to the requirements of the Connecting Europe Facility grant reference: "CEF-Energy-2018-2". It should be noted that this new application does not impact the Company's existing EU grant for FEED ("Front End Engineering Design") works. As announced on 11 October 2018 FEED is progressing ahead of schedule with almost 70% of the pre-established milestones having been achieved.

The application has been submitted for a grant intervention rate of 33.14%. This equates to a grant amount of circa £40 million towards the total construction cost of the Project's first phase of an initial two storage caverns.

The Company will receive notification from CEF-Energy-2018-2 in February 2019 (or such later date as publicly notified by the EU) detailing whether the application was successful, and if so, the level of funding granted. The notification timeframe aligns with the Company's planned H1 2019 programme of activities for final investment decision ("FID"), procurement of a contractor and the commencement of the engineering works.

A key element that must be submitted as part of the grant (for it to be eligible for funding) is an independently prepared Cost Benefit Analysis ("CBA") for the Project. The Company duly commissioned this independent report from Energy Reform Consulting Services and the results demonstrated the clear need for the Project. The report highlighted the fact that just a single day's power outage will cost the UK economy in excess of £1.1 billion at its peak, with an average daily cost of £700 million.

The CBA demonstrates a strong investment to benefit ratio and clearly underpins the Directors' belief that this Project could be a key piece of strategic infrastructure for the UK. A copy of the CBA will be uploaded onto the Company's website by the end of the day tomorrow. Whilst a Brexit "No Deal" generally increases uncertainty, the Directors do not believe that it will affect this application as the UK government (as part of the "no deal" papers published) has stated that it will honour PCI (EU Project of Common Interest) project funding in the event of leaving the EU with no deal.

John Wood, Chief Executive Officer commented "I would like to thank the team for their extremely hard work and efforts in submitting the grant application by the designated deadline and we look forward to receiving the decision in February 2019. We now continue to focus on the last few elements of the FEED works and the conclusio

Based on the RNS two of the Non Exec have gone 'As part of the Company’s decision to focus on antibiotics development, Dr Barry Price and Professor Stephen Davies have today stepped down from the Board of Directors' in addition the Company head count has been reduced.Plans made & executed to reduce costs following failure of DMD. have been carried out.

Physiomics reports record year of income with significant contract wins:
https://www.proactiveinvestors.co.uk/companies/stocktube/10799/physiomics-reports-record-year-of-income-with-significant-contract-wins-10799.html

Released 12:00 10-Oct-2018
Summit Therapeutics to Participate in Upcoming Investor Events

Oxford, UK, and Cambridge, MA, US, 10 October 2018 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that management will participate in two upcoming investor events.

BIO Investor Forum, Mr Glyn Edwards is speaking on the panel “Using Microbiome-Based Therapies to Improve Patient Outcomes,” 10:45am PDT, 17 October 2018 in San Francisco, CA

BTIG Biotech Conference, 25 October 2018 in New York City
At these events, management will conduct one-on-one meetings; there will be no podium presentations..

I topped up this morning an additional 14,250 shares to add to my 57,250 initial investment small beer but it is all I can now afford after my Summit investment (SUMM) tanked but I believe Valirx will come good & it helps my average.For me a Strong Buy at these prices.

Physiomics’ annual revenue doubles thanks to lucrative Merck KGaA contract win:
https://www.proactiveinvestors.co.uk/companies/news/206553/physiomics-annual-revenue-doubles-thanks-to-lucrative-merck-kgaa-contract-win-206553.html

RNS out today
Surrender of Share Options
https://www.londonstockexchange.com/exchange/prices-and-markets/stocks/summary/company-summary/GB00BN40HZ01GBGBXASX1.html?lang=en

I have just looked at the Annual accounts & note the improvement on the previous year & that they are a 'Going Concern' with projected cash flows showing positive after the next 12 months.Hopefully they should show break even in the next financial year.A few more contracts & the SP should start to increase & hopefully todays results will show a SP improvement starting today.

There are now 4 posters relating to this weeks conference posted by Summit see link below:

https://www.summitplc.com/publications/

So agree with you dawski37 now a good time to Buy for those with funds before the SP rockets.

Link correction:
https://www.pharmatimes.com/news/roche_teams_up_with_uks_discuva_for_new_antibiotic_1001606

Detailed below is more information on the Roche/Discuva deal detailing values etc of the initial contract:
Roche teams up with UK's Discuva for new antibiotic 2nd March 2014
http://www.pharmatimes.com/news/roche_teams_up_with_uks_discuva_for_new_antibiotic_1001606
Plus other articles https://www.roche.com/media/releases/med-cor-2014-02-28p.htm
https://www.currentpartnering.com/2014/03/03/roche-inks-pharma-partnering-discuva-191-million/

It is the first RNS announcing a disposal that I have ever seen that does not mention the value of the consideration for a disposal.RNS is incomplete if there is no value they should say so the £value is clearly missing.I hope we will get an update. I am now showing as Hold until we get further news currently I am back to a loss.

Sareum makes strong progress on cancer and autoimmune disease therapies:

http://www.proactiveinvestors.co.uk/companies/news/206048/sareum-makes-strong-progress-on-cancer-and-autoimmune-disease-therapies-206048.html

Sareum Holdings plc
‏@Sareumplc 48m48 minutes agoMore
A Dual Inhibition, a Better Solution: Development of a JAK1/TYK2 inhibitor "dual inhibition of JAK1 and TYK2 can lead to a clinical benefit at a well-tolerated dosing regimen" https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b01397#.W64grTjGt0A.twitter … $SAR.L Sareum #TYK2 #JAK1

0 replies 2 retweets 5 likes